Biocryst Pharmaceuticals (BCRX) Holder Ra Capital Management Upped Position by $9.11 Million as Stock Declined; Infinera (INFN) Valuation Declined While Empyrean Capital Partners LP Trimmed Its Stake

February 17, 2018 - By Vivian Park

Peter Kolchinsky increased its stake in Biocryst Pharmaceuticals (BCRX) by 35.3% based on its latest 2017Q3 regulatory filing with the SEC. Ra Capital Management Llc bought 1.82 million shares as the company’s stock declined 16.46% while stock markets rallied. The hedge fund run by Peter Kolchinsky held 6.98 million shares of the health care company at the end of 2017Q3, valued at $36.60 million, up from 5.16 million at the end of the previous reported quarter. Ra Capital Management Llc who had been investing in Biocryst Pharmaceuticals for a number of months, seems to be bullish on the $488.23 million market cap company. The stock increased 1.85% or $0.09 during the last trading session, reaching $4.96. About 1.53M shares traded or 20.58% up from the average. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since February 17, 2017 and is uptrending. It has outperformed by 58.38% the S&P500.

Michael A. Price decreased its stake in Infinera Corporation (INFN) by 69.52% based on its latest 2017Q3 regulatory filing with the SEC. Empyrean Capital Partners Lp sold 1.74 million shares as the company’s stock declined 19.10% while stock markets rallied. The hedge fund run by Michael A. Price held 761,949 shares of the telecommunications equipment company at the end of 2017Q3, valued at $6.76M, down from 2.50 million at the end of the previous reported quarter. Empyrean Capital Partners Lp who had been investing in Infinera Corporation for a number of months, seems to be less bullish one the $1.47 billion market cap company. The stock increased 2.29% or $0.22 during the last trading session, reaching $9.82. About 2.11 million shares traded or 23.76% up from the average. Infinera Corporation (NASDAQ:INFN) has declined 24.42% since February 17, 2017 and is downtrending. It has underperformed by 41.12% the S&P500.

Since September 18, 2017, it had 0 buys, and 1 sale for $294,035 activity.

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.01, from 1.68 in 2017Q2. It is positive, as 12 investors sold BCRX shares while 24 reduced holdings. 28 funds opened positions while 33 raised stakes. 79.80 million shares or 20.47% more from 66.24 million shares in 2017Q2 were reported. Fmr Llc holds 0% or 3.12M shares in its portfolio. Great West Life Assurance Communications Can reported 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Invesco Limited, a Georgia-based fund reported 956,150 shares. Rhumbline Advisers holds 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) or 95,458 shares. Oakworth Capital Incorporated holds 100 shares. Gsa Prtn Llp stated it has 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Tiaa Cref Inv Mngmt Lc owns 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 501,930 shares. Venbio Select Advisor Lc reported 1.78M shares stake. Renaissance Tech Ltd Liability Co invested in 0% or 226,503 shares. Manufacturers Life Insur The reported 62,981 shares. Moreover, Savings Bank Of Montreal Can has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Northeast Consultants Inc holds 0.04% or 20,000 shares. 119 are held by Envestnet Asset Management Inc. Alliancebernstein LP has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Barclays Public Limited Com accumulated 0% or 14,895 shares.

Among 14 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. BioCryst Pharmaceuticals had 34 analyst reports since August 7, 2015 according to SRatingsIntel. Zacks upgraded the shares of BCRX in report on Friday, August 7 to “Sell” rating. The rating was downgraded by Jefferies to “Buy” on Tuesday, February 9. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Buy” rating by JMP Securities on Tuesday, November 28. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, January 2. The firm has “Buy” rating by J.P. Morgan given on Wednesday, September 6. FBR Capital maintained BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rating on Tuesday, February 9. FBR Capital has “Outperform” rating and $6 target. JP Morgan downgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rating on Tuesday, February 9. JP Morgan has “Neutral” rating and $5 target. JP Morgan upgraded the stock to “Overweight” rating in Wednesday, September 6 report. The firm has “Market Perform” rating by JMP Securities given on Thursday, August 4. The rating was upgraded by Jefferies on Wednesday, September 6 to “Buy”.

Empyrean Capital Partners Lp, which manages about $4.52B and $2.60B US Long portfolio, upped its stake in Investors Bancorp Inc New (NASDAQ:ISBC) by 200,000 shares to 4.20M shares, valued at $57.29 million in 2017Q3, according to the filing. It also increased its holding in Seritage Growth Pptys by 322,675 shares in the quarter, for a total of 1.80 million shares, and has risen its stake in Spdr S&P 500 Etf Tr (SPY).

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>